Heart failure.
暂无分享,去创建一个
[1] E. Braunwald,et al. A tale of coronary artery disease and myocardial infarction. , 2012, The New England journal of medicine.
[2] M. Zile,et al. Plasma Biomarkers That Reflect Determinants of Matrix Composition Identify the Presence of Left Ventricular Hypertrophy and Diastolic Heart Failure , 2011, Circulation. Heart failure.
[3] V. Ambros,et al. Circulating MicroRNAs in cardiovascular disease. , 2011, Circulation.
[4] Robert L Kormos,et al. The Fourth INTERMACS Annual Report: 4,000 implants and counting. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[5] P. Ponikowski,et al. Midregion prohormone adrenomedullin and prognosis in patients presenting with acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. , 2011, Journal of the American College of Cardiology.
[6] Wolfgang A Linke,et al. Myocardial Structure and Function Differ in Systolic and Diastolic Heart Failure , 2006, Circulation.
[7] Eric J Topol,et al. Emerging clinical applications in cardiovascular pharmacogenomics , 2011, Wiley interdisciplinary reviews. Systems biology and medicine.
[8] F. Alla,et al. Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure: Insights From the Randomized Aldactone Evaluation Study (RALES) , 2000, Circulation.
[9] Nilay D Shah,et al. Medication adherence among community-dwelling patients with heart failure. , 2011, Mayo Clinic proceedings.
[10] T. Wieland,et al. Role of RyR2 Phosphorylation at S2814 During Heart Failure Progression , 2012, Circulation research.
[11] S. Houser,et al. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. , 1998, Circulation.
[12] Akshay S. Desai,et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. , 2011, American heart journal.
[13] S. Werns. Effect of Nesiritide in Patients with Acute Decompensated Heart Failure , 2012 .
[14] M. Pfeffer,et al. A sensitive cardiac troponin T assay in stable coronary artery disease. , 2009, The New England journal of medicine.
[15] J. Cleveland,et al. Survival after biventricular assist device implantation: an analysis of the Interagency Registry for Mechanically Assisted Circulatory Support database. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[16] C. Visser,et al. Effects of Calcium, Inorganic Phosphate, and pH on Isometric Force in Single Skinned Cardiomyocytes From Donor and Failing Human Hearts , 2001, Circulation.
[17] D. Burkhoff,et al. Left ventricular assist device support normalizes left and right ventricular beta-adrenergic pathway properties. , 2005, Journal of the American College of Cardiology.
[18] Fred S Apple,et al. Analytical characteristics of high-sensitivity cardiac troponin assays. , 2012, Clinical chemistry.
[19] W. Martinet,et al. Role of autophagy in heart failure associated with aging , 2010, Heart Failure Reviews.
[20] G. Hasenfuss,et al. Cardiac inotropes: current agents and future directions. , 2011, European heart journal.
[21] Udo Hoffmann,et al. A Genetic Risk Score Is Associated With Incident Cardiovascular Disease and Coronary Artery Calcium: The Framingham Heart Study , 2012, Circulation. Cardiovascular genetics.
[22] J. Danesh,et al. B-Type Natriuretic Peptides and Cardiovascular Risk: Systematic Review and Meta-Analysis of 40 Prospective Studies , 2009, Circulation.
[23] D. Burkhoff,et al. Is Myocardial Recovery Possible and How Do You Measure It? , 2012, Current Cardiology Reports.
[24] F. Zannad,et al. Extracellular matrix fibrotic markers in heart failure , 2010, Heart Failure Reviews.
[25] P. Ellinor,et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. , 2006, Journal of the American College of Cardiology.
[26] C. Yancy,et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. , 2006, Journal of the American College of Cardiology.
[27] D. Fatkin,et al. Effects of Mechanical Stress and Carvedilol in Lamin A/C–Deficient Dilated Cardiomyopathy , 2010, Circulation research.
[28] R. Fitzgerald,et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: The NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial , 2011, European journal of heart failure.
[29] Eric Boerwinkle,et al. Cardiac Troponin T Measured by a Highly Sensitive Assay Predicts Coronary Heart Disease, Heart Failure, and Mortality in the Atherosclerosis Risk in Communities Study , 2011, Circulation.
[30] P. Wilson,et al. Predictors of Incident Heart Failure in a Large Insured Population: A One Million Person-Year Follow-Up Study , 2010, Circulation. Heart failure.
[31] M. Pencina,et al. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.
[32] C. di Loreto,et al. Myocyte proliferation in end-stage cardiac failure in humans. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[33] R. Lefkowitz,et al. Intracoronary adenovirus-mediated delivery and overexpression of the beta(2)-adrenergic receptor in the heart : prospects for molecular ventricular assistance. , 2000, Circulation.
[34] C. Ronco,et al. Role of biomarkers in the diagnosis and management of cardio-renal syndromes. , 2012, Seminars in nephrology.
[35] M. Slaughter,et al. Heart transplant vs left ventricular assist device in heart transplant-eligible patients. , 2011, The Annals of thoracic surgery.
[36] G. Fonarow,et al. Working Group on Emergency Department Management of Acute Heart Failure Research Challenges and Opportunities , 2022 .
[37] Carlo Lombardi,et al. Impact of Serial Troponin Release on Outcomes in Patients With Acute Heart Failure: Analysis From the PROTECT Pilot Study , 2011, Circulation. Heart failure.
[38] V. Hasselblad,et al. Troponin I in acute decompensated heart failure: insights from the ASCEND‐HF study , 2011, European journal of heart failure.
[39] P. Anversa,et al. Cardiac stem cells and mechanisms of myocardial regeneration. , 2005, Physiological reviews.
[40] V. Roger,et al. Diastolic stiffness as assessed by diastolic wall strain is associated with adverse remodelling and poor outcomes in heart failure with preserved ejection fraction. , 2012, European heart journal.
[41] S. Priori,et al. FKBP12.6 Deficiency and Defective Calcium Release Channel (Ryanodine Receptor) Function Linked to Exercise-Induced Sudden Cardiac Death , 2003, Cell.
[42] Piotr Ponikowski,et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study , 2009, The Lancet.
[43] D. Levy,et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death , 2004 .
[44] R. Hajjar,et al. Modulation of Cardiac Contractility by the Phopholamban/SERCA2a Regulatome , 2012, Circulation research.
[45] M. Tewari,et al. MicroRNA profiling: approaches and considerations , 2012, Nature Reviews Genetics.
[46] Marissa Miller,et al. Long-term mechanical circulatory support (destination therapy): on track to compete with heart transplantation? , 2012, The Journal of thoracic and cardiovascular surgery.
[47] S. Rubin,et al. Inflammatory Markers and Onset of Cardiovascular Events: Results From the Health ABC Study , 2003, Circulation.
[48] I. König,et al. Genetic Association Study Identifies HSPB7 as a Risk Gene for Idiopathic Dilated Cardiomyopathy , 2010, PLoS genetics.
[49] D. Mozaffarian,et al. Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction: The American Heart Association's Strategic Impact Goal Through 2020 and Beyond , 2010, Circulation.
[50] P. Ponikowski,et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. , 2010, The New England journal of medicine.
[51] G. Calin,et al. MicroRNA history: discovery, recent applications, and next frontiers. , 2011, Mutation research.
[52] Ranjit John,et al. Bleeding and Thrombosis in Patients With Continuous-Flow Ventricular Assist Devices , 2012, Circulation.
[53] M. Zhan,et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. , 2010, JAMA.
[54] Y. Rosenberg,et al. Cardiovascular Pharmacogenomics: Current Status and Future Directions—Report of a National Heart, Lung, and Blood Institute Working Group , 2012, Journal of the American Heart Association.
[55] E. Olson,et al. Therapeutic Inhibition of miR-208a Improves Cardiac Function and Survival During Heart Failure , 2011, Circulation.
[56] Harlan M Krumholz,et al. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. , 2011, JAMA.
[57] L. Fauchier,et al. A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. , 2011, European heart journal.
[58] G. Ewald,et al. Outcomes in Advanced Heart Failure Patients With Left Ventricular Assist Devices for Destination Therapy , 2012, Circulation. Heart failure.
[59] D. Terentyev,et al. The relationship between arrhythmogenesis and impaired contractility in heart failure: role of altered ryanodine receptor function. , 2011, Cardiovascular research.
[60] L. Zanolla,et al. Cardiac troponin I as diagnostic and prognostic marker in severe heart failure. , 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[61] M. Slaughter,et al. Clinical, molecular, and genomic changes in response to a left ventricular assist device. , 2011, Journal of the American College of Cardiology.
[62] Christopher Zimmer,et al. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. , 2009, European heart journal.
[63] M C Oz,et al. Long-term use of a left ventricular assist device for end-stage heart failure. , 2001, The New England journal of medicine.
[64] N. Mehta. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. , 2011, Circulation. Cardiovascular genetics.
[65] J. Teerlink. Ivabradine in heart failure—no paradigm SHIFT…yet , 2010, The Lancet.
[66] Harlan M. Krumholz,et al. Recent National Trends in Readmission Rates After Heart Failure Hospitalization , 2010, Circulation. Heart failure.
[67] S. Normand,et al. Thirty-Day Outcomes in Medicare Patients With Heart Failure at Heart Transplant Centers , 2010, Circulation. Heart failure.
[68] C. Camargo,et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. , 2005, The American journal of cardiology.
[69] V. Roger,et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.
[70] L. Tavazzi,et al. Serial Measurement of Cardiac Troponin T Using a Highly Sensitive Assay in Patients With Chronic Heart Failure: Data From 2 Large Randomized Clinical Trials , 2012, Circulation.
[71] S. Réhman,et al. Independent and incremental prognostic value of multimarker testing in acute dyspnea: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. , 2008, Clinica chimica acta; international journal of clinical chemistry.
[72] M. Pencina,et al. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation , 2004, Statistics in medicine.
[73] C. Ward,et al. Leaky Ca2+ release channel/ryanodine receptor 2 causes seizures and sudden cardiac death in mice. , 2008, The Journal of clinical investigation.
[74] V. Jeevanantham,et al. Adult Bone Marrow Cell Therapy Improves Survival and Induces Long-Term Improvement in Cardiac Parameters: A Systematic Review and Meta-Analysis , 2012, Circulation.
[75] P. Ponikowski,et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. , 2010, Journal of the American College of Cardiology.
[76] P. Nguyen,et al. Safe Genetic Modification of Cardiac Stem Cells Using a Site-Specific Integration Technique , 2012, Circulation.
[77] Anton J. Enright,et al. Targeted Deletion of MicroRNA-22 Promotes Stress-Induced Cardiac Dilation and Contractile Dysfunction , 2012, Circulation.
[78] A. Wu,et al. Multiple Biomarkers for Risk Prediction in Chronic Heart Failure , 2012, Circulation. Heart failure.
[79] Istvan Edes,et al. Cardiomyocyte Stiffness in Diastolic Heart Failure , 2005, Circulation.
[80] S. Reiken,et al. Role of chronic ryanodine receptor phosphorylation in heart failure and β-adrenergic receptor blockade in mice. , 2010, The Journal of clinical investigation.
[81] EmileMissov,et al. Circulating Cardiac Troponin I in Severe Congestive Heart Failure , 1997 .
[82] Peipei Ping,et al. Cardiovascular proteomics: tools to develop novel biomarkers and potential applications. , 2006, Journal of the American College of Cardiology.
[83] R. Gerszten,et al. Sildenafil Improves Exercise Capacity and Quality of Life in Patients With Systolic Heart Failure and Secondary Pulmonary Hypertension , 2007 .
[84] A. Ishani,et al. Renal Biomarkers of Kidney Injury in Cardiorenal Syndrome , 2011, Current heart failure reports.
[85] A. Cohen-Solal,et al. Trends in death attributed to heart failure over the past two decades in Europe , 2012, European journal of heart failure.
[86] G. Noon,et al. Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support : A potential mechanism for cardiac recovery. , 1999, Circulation.
[87] K. Weber,et al. Cellular and molecular pathways to myocardial necrosis and replacement fibrosis , 2010, Heart Failure Reviews.
[88] W. Frishman,et al. Left Ventricular Assist Device and Drug Therapy for the Reversal of Heart Failure , 2007 .
[89] J. Cleland,et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial , 2011, The Lancet.
[90] P. Ponikowski,et al. Mid‐regional pro‐adrenomedullin as a novel predictor of mortality in patients with chronic heart failure , 2010, European journal of heart failure.
[91] K. Swedberg,et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. , 2007, JAMA.
[92] P. Schulze,et al. Episodes of Acute Heart Failure Syndrome Are Associated With Increased Levels of Troponin and Extracellular Matrix Markers , 2010, Circulation. Heart failure.
[93] Simon Maybaum,et al. Cardiac recovery during continuous-flow left ventricular assist device support: some good news from across the Atlantic. , 2011, Circulation.
[94] Richard T. Lee,et al. Complementary Roles for Biomarkers of Biomechanical Strain ST2 and N-Terminal Prohormone B-Type Natriuretic Peptide in Patients With ST-Elevation Myocardial Infarction , 2008, Circulation.
[95] A. Maisel,et al. Breathing not properly 10 years later: what we have learned and what we still need to learn. , 2012, Journal of the American College of Cardiology.
[96] H. Ly,et al. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. , 2008, Journal of the American College of Cardiology.
[97] David A. Kass,et al. Tackling heart failure in the twenty-first century , 2008, Nature.
[98] Magdi H. Yacoub,et al. Reversal of Severe Heart Failure With a Continuous-Flow Left Ventricular Assist Device and Pharmacological Therapy: A Prospective Study , 2011, Circulation.
[99] S. Solomon,et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial , 2012, The Lancet.
[100] Mark A Sussman,et al. Enhancement of Myocardial Regeneration Through Genetic Engineering of Cardiac Progenitor Cells Expressing Pim-1 Kinase , 2009, Circulation.
[101] M. Cheitlin. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study , 2012 .
[102] Piotr Ponikowski,et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial , 2013, The Lancet.
[103] T. Carrel,et al. S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes. , 2011, Journal of the American College of Cardiology.
[104] Harvard Medical School,et al. Targeting Phospholamban by Gene Transfer in Human Heart Failure , 2002, Circulation.
[105] A. Katz,et al. New molecular mechanism in diastolic heart failure. , 2006, Circulation.
[106] B. Bozkurt,et al. Biomarkers of inflammation in heart failure , 2010, Heart Failure Reviews.
[107] J. Spertus,et al. A GRK5 polymorphism that inhibits β-adrenergic receptor signaling is protective in heart failure , 2008, Nature Network Boston.
[108] Marcus F Stoddard,et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial , 2011, The Lancet.
[109] A. Khaghani,et al. Long-term outcomes of patients bridged to recovery versus patients bridged to transplantation. , 2012, The Journal of thoracic and cardiovascular surgery.
[110] Inflammatory Markers and Risk of Heart Failure in Elderly Subjects Without Prior Myocardial Infarction: The Framingham Heart Study , 2003 .
[111] M. Cheitlin. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study , 2011 .
[112] A. Wu,et al. High-Sensitivity ST2 for Prediction of Adverse Outcomes in Chronic Heart Failure , 2011, Circulation. Heart failure.
[113] Nancy M Albert,et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. , 2010, Journal of cardiac failure.
[114] H. Brunner-La Rocca,et al. Biomarker Guided Therapy in Chronic Heart Failure. , 2015, Cardiac failure review.
[115] J. Januzzi,et al. Emerging biomarkers in heart failure. , 2012, Clinical chemistry.
[116] H. Watkins,et al. Inherited cardiomyopathies. , 2011, The New England journal of medicine.
[117] P. D. de Tombe,et al. Beneficial effects of SR33805 in failing myocardium. , 2011, Cardiovascular research.
[118] S. Solomon,et al. Evaluation of Multiple Biomarkers of Cardiovascular Stress for Risk Prediction and Guiding Medical Therapy in Patients With Stable Coronary Disease , 2012, Circulation.
[119] P. Ponikowski,et al. Increased 90-Day Mortality in Patients With Acute Heart Failure With Elevated CopeptinClinical Perspective , 2011 .
[120] V. Roger,et al. The Heart Failure Epidemic , 2010, International journal of environmental research and public health.
[121] E. Braunwald,et al. Studies on the Function of the Adrenergic Nerve Endings in the Heart , 1963, Circulation.
[122] A. Cohen-Solal,et al. Unbiased plasma proteomics for novel diagnostic biomarkers in cardiovascular disease: identification of quiescin Q6 as a candidate biomarker of acutely decompensated heart failure. , 2012, European heart journal.
[123] V. Roger,et al. Progression of left ventricular diastolic dysfunction and risk of heart failure. , 2011, JAMA.
[124] Q. Truong,et al. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. , 2012, European heart journal.
[125] Colin Simpson,et al. Long-Term Trends in First Hospitalization for Heart Failure and Subsequent Survival Between 1986 and 2003: A Population Study of 5.1 Million People , 2009, Circulation.
[126] E. Braunwald. Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. , 1997, The New England journal of medicine.
[127] William T. Abraham,et al. Focused Update : ACCF / AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults , 2013 .
[128] C. Thieke,et al. Long-term survival of cancer patients compared to heart failure and stroke: A systematic review , 2010, BMC Cancer.
[129] J. Michel,et al. Constitutive Cardiac Overexpression of Sarcoplasmic/Endoplasmic Reticulum Ca2+-ATPase Delays Myocardial Failure After Myocardial Infarction in Rats at a Cost of Increased Acute Arrhythmias , 2004, Circulation.
[130] D. DiFrancesco. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. , 2006, Pharmacological research.
[131] R. Hetzer,et al. Pre-Explant Stability of Unloading-Promoted Cardiac Improvement Predicts Outcome After Weaning From Ventricular Assist Devices , 2012, Circulation.
[132] L. Mestroni,et al. Truncations of titin causing dilated cardiomyopathy. , 2012, The New England journal of medicine.
[133] J. Burnett,et al. Adrenomedullin: potential in physiology and pathophysiology. , 2000, Life sciences.
[134] H. F. Wood,et al. A study of C-reactive protein in the serum of patients with congestive heart failure. , 1956, American heart journal.
[135] S. Houser,et al. Regression of cellular hypertrophy after left ventricular assist device support. , 1998, Circulation.
[136] Jonathan Seidman,et al. Genetic causes of human heart failure. , 2005, The Journal of clinical investigation.
[137] Daniel Berman,et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial , 2012, The Lancet.
[138] D. Levy,et al. Multimarker Approach for the Prediction of Heart Failure Incidence in the Community , 2010, Circulation.
[139] Y. Pinto,et al. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. , 2011, Cardiovascular research.
[140] G. Ginsburg,et al. Clinical application of cardiovascular pharmacogenetics. , 2012, Journal of the American College of Cardiology.
[141] M. Cheitlin. PDE5 Inhibition With Sildenafil Improves Left Ventricular Diastolic Function, Cardiac Geometry, and Clinical Status in Patients With Stable Systolic Heart Failure: Results of a 1-Year, Prospective, Randomized, Placebo-Controlled Study , 2011 .
[142] B. Gage,et al. Effects of Phosphodiesterase Type 5 Inhibition on Systemic and Pulmonary Hemodynamics and Ventricular Function in Patients With Severe Symptomatic Aortic Stenosis , 2012, Circulation.
[143] Daniel Levy,et al. Long-term trends in the incidence of and survival with heart failure. , 2002, The New England journal of medicine.
[144] D. Mozaffarian,et al. Heart disease and stroke statistics--2012 update: a report from the American Heart Association. , 2012, Circulation.
[145] E. Braunwald,et al. Contractile State of Cardiac Muscle Obtained from Cats with Experimentally Produced Ventricular Hypertrophy and Heart Failure , 1967, Circulation research.
[146] Garth M. Beache,et al. Administration of Cardiac Stem Cells in Patients With Ischemic Cardiomyopathy: The SCIPIO Trial Surgical Aspects and Interim Analysis of Myocardial Function and Viability by Magnetic Resonance , 2012, Circulation.
[147] A. Owens,et al. The year in heart failure. , 2011, Journal of the American College of Cardiology.
[148] S. Manzano-Fernández,et al. Soluble ST2, high‐sensitivity troponin T‐ and N‐terminal pro‐B‐type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure , 2011, European journal of heart failure.
[149] R. Hershberger,et al. Where genome meets phenome: rationale for integrating genetic and protein biomarkers in the diagnosis and management of dilated cardiomyopathy and heart failure. , 2012, Journal of the American College of Cardiology.
[150] G. Jakl,et al. Complementary role of copeptin and high‐sensitivity troponin in predicting outcome in patients with stable chronic heart failure , 2011, European journal of heart failure.
[151] T. Eschenhagen,et al. β-Adrenergic stimulation and myocardial function in the failing heart , 2009, Heart Failure Reviews.
[152] S. Bagshaw,et al. Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials. , 2010, International journal of cardiology.
[153] S. Blankenberg,et al. Genomewide association studies in cardiovascular disease--an update 2011. , 2012, Clinical chemistry.
[154] B. Pathik,et al. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. , 2006, American heart journal.
[155] S. Reiken,et al. Phosphodiesterase 4D Deficiency in the Ryanodine-Receptor Complex Promotes Heart Failure and Arrhythmias , 2005, Cell.
[156] C. Croce,et al. MicroRNA-133 controls cardiac hypertrophy , 2007, Nature Medicine.
[157] A. Mebazaa,et al. Levosimendan: from basic science to clinical practice , 2009, Heart Failure Reviews.
[158] D. Cox,et al. Cardiac Myosin Activation: A Potential Therapeutic Approach for Systolic Heart Failure , 2011, Science.
[159] S. Russell,et al. Advanced heart failure treated with continuous-flow left ventricular assist device. , 2009, The New England journal of medicine.
[160] Klitos Konstantinidis,et al. Mechanisms of cell death in heart disease. , 2012, Arteriosclerosis, thrombosis, and vascular biology.
[161] J. Cohn,et al. Prognostic Value of Very Low Plasma Concentrations of Troponin T in Patients With Stable Chronic Heart Failure , 2007, Circulation.
[162] P. Centofanti,et al. Advanced heart failure in critical patients (INTERMACS 1 and 2 levels): ventricular assist devices or emergency transplantation? , 2012, Interactive cardiovascular and thoracic surgery.
[163] M. Yacoub,et al. Bridge to recovery and the search for decision nodes. , 2011, Circulation. Heart failure.
[164] G. Navis,et al. Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate , 2010, Heart.
[165] F. Vandeput,et al. Phosphodiesterase inhibition in heart failure , 2009, Heart Failure Reviews.
[166] Arjun Deb,et al. Mesenchymal stem cells overexpressing Akt dramatically repair infarcted myocardium and improve cardiac function despite infrequent cellular fusion or differentiation. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[167] A. Marks,et al. The ryanodine receptor in cardiac physiology and disease. , 2010, Advances in pharmacology.
[168] Deepak L. Bhatt,et al. Presence of Atrial Fibrillation Is Independently Associated With Adverse Outcomes in Patients Hospitalized With Heart Failure: An Analysis of Get With The Guidelines–Heart Failure , 2012, Circulation. Heart failure.
[169] T. Weber,et al. Gene Therapy for Heart Failure , 2012, Circulation research.
[170] Godfrey L. Smith,et al. K201 improves aspects of the contractile performance of human failing myocardium via reduction in Ca2+ leak from the sarcoplasmic reticulum , 2009, Basic Research in Cardiology.
[171] D. Mancini,et al. Effects of Continuous-Flow Versus Pulsatile-Flow Left Ventricular Assist Devices on Myocardial Unloading and Remodeling , 2011, Circulation. Heart failure.
[172] Pranav Loyalka,et al. Use of an Intrapericardial, Continuous-Flow, Centrifugal Pump in Patients Awaiting Heart Transplantation , 2012, Circulation.
[173] G. Reeder,et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. , 1986, Science.
[174] Anders Larsson,et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. , 2008, The New England journal of medicine.
[175] P. Ponikowski,et al. Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes: Lessons Learned and Directions Forward , 2010, Circulation. Heart failure.
[176] Samuel Bernard,et al. Evidence for Cardiomyocyte Renewal in Humans , 2008, Science.
[177] D. Hodge,et al. The Natural History of Preclinical Diastolic Dysfunction: A Population Based Study , 2010 .
[178] P. Buttrick,et al. Reverse Remodeling With Left Ventricular Assist Devices: A Review of Clinical, Cellular, and Molecular Effects , 2011, Circulation. Heart failure.
[179] G. Lewis,et al. Sildenafil Improves Exercise Hemodynamics and Oxygen Uptake in Patients With Systolic Heart Failure , 2006, Circulation.
[180] H. Krum,et al. Novel therapies in acute and chronic heart failure. , 2012, Pharmacology & therapeutics.
[181] C A Beltrami,et al. Apoptosis in the failing human heart. , 1997, The New England journal of medicine.
[182] E. Braunwald,et al. Biomarkers in heart failure. , 2008, The New England journal of medicine.
[183] V. Roger,et al. Lifetime Costs of Medical Care After Heart Failure Diagnosis , 2011, Circulation. Cardiovascular quality and outcomes.